Last updated on July 2019

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)


Brief description of study

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

 

Detailed Study Description

The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with bendamustine and obinutuzumab in relapsed or refractory follicular lymphoma (FL).

 

Clinical Study Identifier: TX151684

Find a site near you

Start Over

Greenvile Health System

Located in: Greenvile, SC USA
  Connect »

Clinical Research Alliance

Located in: Lake Success, NY USA
  Connect »

Banner Health

Located in: Gilbert, AZ USA
  Connect »

Summit Medical Group

Located in: Morristown, NJ USA
  Connect »

University of Kansas Cancer Center

Located in: Kansas City, MO USA
  Connect »

Aarhus Universitets Hospital

Located in: Aarhus, Denmark
  Connect »

The Finsen Centre, National Hospital

Located in: Copenhagen, Denmark
  Connect »

FN Ostrava

Located in: Ostrava, Czech Republic
  Connect »

Azienda Ospedaliera Mater Domini

Located in: Catanzaro, Catanzaro Italy
  Connect »

Scripps Green Hospital

Located in: La Jolla, CA USA
  Connect »